{
    "clinical_study": {
        "@rank": "53694", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Nasal spray 4 times a day over 4 to 10 days"
            }, 
            {
                "arm_group_label": "Iota-Carrageenan nasal spray", 
                "arm_group_type": "Experimental", 
                "description": "Nasal spray 4 times a day over 4 to 10 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this clinical trial is to investigate the effect of Iota-Carrageenan treatment on\n      cold symptoms. The effect of treatment on the duration of the cold and the patients viral\n      load plus cytokine level indicating the inflammatory response will be analyzed."
        }, 
        "brief_title": "Iota-Carrageenan Nasal Spray in Common Cold", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Common Cold", 
        "condition_browse": {
            "mesh_term": "Common Cold"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients consider that they are in an early stage of common cold with symptoms of no\n             more than 48 hours duration\n\n          -  Symptom score of equal or more than 1 for for at least one of the symptoms sore\n             throat, runny nose and blocked nose on a 0-3 verbal rating scale\n\n          -  Total symptom score of equal or less 9 for symptoms headache, muscle ache,\n             chilliness, sore throat, blocked nose, runny nose, cough, and sneezing measured on a\n             0-3 verbal rating scale\n\n          -  Patients agree to refrain from taking any products intended to prevent, intervene in,\n             or treat cough/colds/flu, starting at study entry and continuing through day 10 (e.g.\n             those containing zinc, Echinacea); use of a daily multivitamin is allowed.\n\n        Exclusion criteria:\n\n          -  Known hypersensitivity or are allergic to any component of the test device\n\n          -  Clinically significant cardiovascular, endocrinological, neurological, respiratory,\n             gastrointestinal disease or history or any current disease that is considered by the\n             investigator as a reason for exclusion e.g. current allergic rhinitis, chronic\n             obstructive pulmonary disease\n\n          -  Severe nasal septum deviation or other condition that could cause nasal obstruction\n             such as the presence of nasal polyps.\n\n          -  History of nasal or sinus surgery that in the opinion of the investigator may\n             influence symptom scores\n\n          -  Taking any prescribed medication other than for contraception, that is considered by\n             the investigator as a reason for exclusion e.g. systemic steroids, intranasal\n             medicines, antibiotics\n\n          -  Common cold or flu like symptoms for more than 48 hours.\n\n          -  Recent (within the previous 2 days) intake of a common cold medicine that in the\n             opinion of the investigator may influence symptom scores (analgesics, nasal\n             decongestants, cough medicines)\n\n          -  Current smoker (more than 10 cigarettes a day)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944631", 
            "org_study_id": "1326.1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Nasal spray saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Iota-Carrageenan nasal spray", 
                "description": "Nasal spray containing 1.20 g/l Iota-Carrageenan in saline", 
                "intervention_name": "Iota-Carrageenan", 
                "intervention_type": "Device"
            }
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cardiff", 
                    "country": "United Kingdom"
                }, 
                "name": "1326.1.44001 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Total symptom score (TSS) of the 8 single common cold symptom scores (headache, muscle ache, chilliness, sore throat, blocked nose, runny nose, cough and sneezing), mean over days 2 to 4 (TSS2-4)", 
            "safety_issue": "No", 
            "time_frame": "Day 2 to day 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944631"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Sum of 3 single systemic common cold symptom scores (headache, muscle ache, chilliness), mean over days 2 to 4", 
                "safety_issue": "No", 
                "time_frame": "Day 2 to day 4"
            }, 
            {
                "measure": "Sum of 5 single local common cold symptom scores (sore throat, blocked nose, runny nose, cough and sneezing), mean over days 2 to 4", 
                "safety_issue": "No", 
                "time_frame": "Day 2 to day 4"
            }, 
            {
                "measure": "Area under the curve (AUC) over the 10-day period for the TSS", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to day 10"
            }, 
            {
                "measure": "Duration of the cold", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 days"
            }, 
            {
                "measure": "Patient overall assessment of efficacy", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to day 10"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}